Journal Mobile Options
Table of Contents
Vol. 85, No. 4, 2007
Issue release date: July 2007
Neuroendocrinology 2007;85:232–241

Adipokine Gene Expression in a Novel Hypothalamic Neuronal Cell Line: Resistin-Dependent Regulation of Fasting-Induced Adipose Factor and SOCS-3

Brown R. · Imran S.A. · Belsham D.D. · Ur E. · Wilkinson M.
aDepartments of Obstetrics and Gynaecology, bPhysiology and Biophysics and cDivision of Endocrinology and Metabolism, Faculty of Medicine, Dalhousie University, Halifax, N.S., and dDepartments of Physiology, Obstetrics and Gynaecology, and Medicine, University of Toronto, Toronto, Ont., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Adipokines such as leptin, resistin, and fasting-induced adipose factor (FIAF) are secreted by adipocytes, but their expression is also detectable in the brain and pituitary. The role of central adipokines remains elusive, but we speculate that they may modulate those hypothalamic signaling pathways that control energy homeostasis. Here we describe experiments to test this in which we exploited a novel hypothalamic neuronal cell line (N-1) that expresses a variety of neuropeptides and receptors that are known to be implicated in appetite regulation. Using real-time RT-PCR, we confirmed that N-1 neurons express resistin (rstn) and fiaf, as well as suppressor of cytokine signaling-3 (socs-3), a feedback inhibitor of leptin signaling. Treating N-1 cells with recombinant resistin (200 ng/ml, 30 min) reduced both fiaf (25%, p < 0.005) and socs-3 (29%, p < 0.005) mRNA levels, and similar reductions in fiaf (40%, p < 0.001) and socs-3 (25%, p < 0.001) resulted following the overexpression of resistin. Conversely, when RNA interference (RNAi) was used to reduce endogenous rstn levels (–60%, p < 0.005), fiaf and socs-3 expression was increased (46 and 65% respectively, p < 0.005). A similar reduction in rstn mRNA was achieved using RNAi in differentiated 3T3-L1 adipocytes, and this manipulation also reduced fiaf and socs-3 expression (–53, –21 and –20% respectively, p < 0.005). In contrast, although RNAi successfully reduced fiaf mRNA by 50% (p < 0.001) in N-1 cells and 40% (p < 0.001) in 3T3-L1 cells, there was no effect on rstn or socs-3 mRNA. These data suggest that resistin exerts a novel autocrine/paracrine control over fiaf and socs-3 expression in both 3T3-L1 adipocytes and N-1 neurons. Such a mechanism could be part of the central feedback system that modulates the effects of adipokines, and other adiposity signals, implicated in hypothalamic energy homeostasis. However, it remains to be determined whether these in vitro results can be translated to the control of adipokine expression in brain and adipose tissue.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548–2556.
  2. Himms-Hagen J: Physiological roles of the leptin endocrine system: differences between mice and humans. Crit Rev Clin Lab Sci 1999;36:575–655.
  3. Trayhurn P, Wood IS: Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–355.
  4. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W: Characterization of the fasting-induced adipose factor fiaf, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000;275:28488–28493.
  5. Funahashi H, Yada T, Suzuki R, Shioda S: Distribution, function, and properties of leptin receptors in the brain. Int Rev Cytol 2003;224:1–27.
  6. Wilkinson M, Morash B, Ur E: The brain is a source of leptin. Front Horm Res 2000;26:106–125.
  7. Ur E, Wilkinson DA, Morash BA, Wilkinson M: Leptin immunoreactivity is localized to neurons in rat brain. Neuroendocrinology 2002;75:264–272.
  8. Beretta E, Dube MG, Kalra PS, Kalra SP: Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: effects on serum ghrelin and appetite-regulating genes. Pediatr Res 2002;52:189–198.
  9. Knerr I, Schuster S, Nomikos P, Buchfelder M, Dotsch J, Schoof E, Fahlbusch R, Rascher W: Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans. Neuropathol Appl Neurobiol 2001;27:215–222.
  10. Ehrhardt RA, Bell AW, Boisclair YR: Spatial and developmental regulation of leptin in fetal sheep. Am J Physiol 2002;282:R1628–R1635.
  11. Smolinska N, Przala J, Kaminski T, Siawrys G, Gajewska A, Kochman K, Okrasa S: Leptin gene expression in the hypothalamus and pituitary of pregnant pigs. Neuro Endocrinol Lett 2004;25:191–195.
  12. Kaminski T, Smolinska N, Gajewska A, Siawrys G, Okrasa S, Kochman K, Przala J: Leptin and long form of leptin receptor genes expression in the hypothalamus and pituitary during the luteal phase and early pregnancy in pigs. J Physiol Pharmacol 2006;57:95–108.
  13. Li HY, Wang LL, Yeh RS: Leptin immunoreactivity in the central nervous system in normal and diabetic rats. Neuroreport 1999;10:437–442.
  14. Johnson RM, Johnson TM, Londraville RL: Evidence for leptin expression in fishes. J Exp Zool 2000;286:718–724.
  15. Boswell T, Dunn IC, Wilson PW, Joseph N, Burt DW, Sharp PJ: Identification of a non-mammalian leptin-like gene: characterization and expression in the tiger salamander (Ambystoma tigrinum). Gen Comp Endocrinol 2006;146:157–166.
  16. Brown R, Morash B, Ur E, Wilkinson M: Rnai-mediated silencing of leptin gene expression increases cell death in c6 glioblastoma cells. Brain Res Mol Brain Res 2005;139:357–360.
  17. Eikelis N, Esler M: The neurobiology of human obesity. Exp Physiol 2005;90:673–682.
  18. Russo VC, Metaxas S, Kobayashi K, Harris M, Werther GA: Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 2004;145:4103–4112.
  19. Morash BA, Wilkinson D, Ur E, Wilkinson M: Resistin expression and regulation in mouse pituitary. FEBS Lett 2002;526:26–30.
  20. Morash BA, Ur E, Wiesner G, Roy J, Wilkinson M: Pituitary resistin gene expression: effects of age, gender and obesity. Neuroendocrinology 2004;79:149–156.
  21. Wiesner G, Morash BA, Ur E, Wilkinson M: Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 2004;180:R1–R6.
  22. Wilkinson M, Wilkinson D, Wiesner G, Morash B, Ur E: Hypothalamic resistin immunoreactivity is reduced by obesity in the mouse: co-localization with α-melanostimulating hormone. Neuroendocrinology 2005;81:19–30.
  23. Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A, Williams LM, Dickson SL, Dieguez C: Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol 2005;153:R1–R5.
  24. Ort T, Arjona AA, MacDougall JR, Nelson PJ, Rothenberg ME, Wu F, Eisen A, Halvorsen YD: Recombinant human fizz3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology 2005;146:2200–2209.
  25. Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, Germain S: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003;162:1521–1528.
  26. Maddineni S, Metzger S, Ocon O, Hendricks G 3rd, Ramachandran R: Adiponectin gene is expressed in multiple tissues in the chicken: food deprivation influences adiponectin messenger ribonucleic acid expression. Endocrinology 2005;146:4250–4256.
  27. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–769.
  28. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS: Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524–529.
  29. Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H: Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (ay/a) obese mice. Diabetes 2003;52:2266–2273.
  30. Brunetti L, Orlando G, Recinella L, Michelotto B, Ferrante C, Vacca M: Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Eur J Pharmacol 2004;493:41–44.
  31. Ahima RS, Qi Y, Singhal NS: Adipokines that link obesity and diabetes to the hypothalamus. Prog Brain Res 2006;153:155–174.
  32. Singhal NS, Qi Y, Lazar MA, Ahima RS: Resistin regulates hepatic glucose metabolism via a central mechanism. Society for Neuroscience, 2006.
  33. Belsham DD, Cai F, Cui H, Smukler SR, Salapatek AM, Shkreta L: Generation of a phenotypic array of hypothalamic neuronal cell models to study complex neuroendocrine disorders. Endocrinology 2004;145:393–400.
  34. Song H, Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Fukushima Y, Kikuchi M, Shimano H, Yamada N, Oka Y, Asano T: Resistin is regulated by c/ebps, ppars, and signal-transducing molecules. Biochem Biophys Res Commun 2002;299:291–298.
  35. Sato N, Kobayashi K, Inoguchi T, Sonoda N, Imamura M, Sekiguchi N, Nakashima N, Nawata H: Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 2005;146:273–279.
  36. Xu A, Lam MC, Chan KW, Wang Y, Zhang J, Hoo RL, Xu JY, Chen B, Chow WS, Tso AW, Lam KS: Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 2005;102:6086–6091.
  37. Brown R, Wiesner G, Ur E, Wilkinson M: Pituitary resistin gene expression is upregulated in vitro and in vivo by dexamethasone but is unaffected by rosiglitazone. Neuroendocrinology 2005;81:41–48.
  38. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA: Activation of socs-3 by resistin. Mol Cell Biol 2005;25:1569–1575.
  39. Wiesner G, Brown RE, Robertson GS, Imran SA, Ur E, Wilkinson M: Increased expression of the adipokine genes resistin and fasting-induced adipose factor in hypoxic/ischaemic mouse brain. Neuroreport 2006;17:1195–1198.
  40. Bond BC, Virley DJ, Cairns NJ, Hunter AJ, Moore GB, Moss SJ, Mudge AW, Walsh FS, Jazin E, Preece P: The quantification of gene expression in an animal model of brain ischaemia using Taqman real-time RT-PCR. Brain Res Mol Brain Res 2002;106:101–116.
  41. Stewart MJ, Smoak K, Blum MA, Sherry B: Basal and reovirus-induced β-interferon (IFN-β) and IFN-β-stimulated gene expression are cell type specific in the cardiac protective response. J Virol 2005;79:2979–2987.
  42. Cui H, Cai F, Belsham DD: Anorexigenic hormones leptin, insulin, and α-melanocyte-stimulating hormone directly induce neurotensin (nt) gene expression in novel nt-expressing cell models. J Neurosci 2005;25:9497–9506.
  43. Sahu A: Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004;145:2613–2620.
  44. Jackson AL, Linsley PS: Noise amidst the silence: off-target effects of sirnas? Trends Genet 2004;20:521–524.
  45. Munzberg H, Flier JS, Bjorbaek C: Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004;145:4880–4889.
  46. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C, Flier JS: Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of socs-3. Nat Med 2004;10:734–738.
  47. Kersten S: Regulation of lipid metabolism via angiopoietin-like proteins. Biochem Soc Trans 2005;33:1059–1062.
  48. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718–15723.
  49. Wiesner G, Brown R, Robertson G, Ur E, Wilkinson M: Increased expression of the adipokines resistin and fiaf in hypoxic/ischemic mouse brain. Neuroreport 2006;17:1195–1198.
  50. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, Friedman JM, Holmes WE, Spiegelman BM: Peroxisome proliferator-activated receptor-γ target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000;20:5343–5349.
  51. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004;53:1937–1941.
  52. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA: Regulation of fasted blood glucose by resistin. Science 2004;303:1195–1198.
  53. Palanivel R, Maida A, Liu Y, Sweeney G: Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006;49:183–190.
  54. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848–4856.
  55. Lee JH, Bullen JW Jr, Stoyneva VL, Mantzoros CS: Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia. Am J Physiol 2005;288:E625–E632.
  56. Kim S, Moustaid-Moussa N: Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr 2000;130:3110S–3115S.
  57. Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998;22:1145–1158.
  58. Fu Y, Luo N, Klein RL, Garvey WT: Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005;46:1369–1379.
  59. Gong H, Ni Y, Guo X, Fei L, Pan X, Guo M, Chen R: Resistin promotes 3t3-l1 preadipocyte differentiation. Eur J Endocrinol 2004;150:885–892.
  60. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L: Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304:1154–1158.
  61. Spranger J, Verma S, Gohring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschop M, Banks WA: Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 2006;55:141–147.
  62. Wilkinson M, Brown R, Imran SA, Ur E: Adipokine gene expression in brain and pituitary gland. Neuroendocrinology 2007, submitted.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50